5)中介龙头:贝壳-W、我爱我家。 毎日晨报 银河观点集萃 2024年9月 26日 | --- | --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report maintains a "Recommended" rating for the mechanical equipment industry [3][56]. Core Insights - The mechanical equipment index rose by 1.58% last week, while the Shanghai Composite Index increased by 1.32% and the ChiNext Index by 0.09%. The mechanical equipment sector ranked 15th among all 31 industries in terms of performance [1][10]. - Excavator sales are expected to increase by approximately 12% year-on-year in September 2024, with domestic sales projected at 7,300 units (up nearly 17%) and exports at 8,700 units (up nearly 9%) [2]. - The report highlights significant investment opportunities in large-scale equipment updates, overseas expansion of equipment, and AI applications, particularly in humanoid robots and AI hardware [3]. Summary by Sections Market Overview - The mechanical equipment index's valuation level is at 23.4 times earnings, excluding negative values [1][10]. - The top-performing sectors last week included engineering machinery, injection molding machines, and oil and gas development equipment [1][11]. Excavator Market - The overall excavator sales in China for the first nine months of 2024 are expected to decline by about 1%, with domestic sales growing over 8% and exports decreasing by 8% [2]. - The excavator market has been in a downward cycle since 2022, with 2024 anticipated to be a bottoming year for the domestic market, leading to a potential new replacement cycle starting in 2025 [2]. Humanoid Robots - 1X Technologies announced a new generative model for training robotic systems more efficiently in simulated environments, which could enhance the applicability and accuracy of humanoid robots [2]. - The report suggests that humanoid robots are ideal carriers for AGI, and the ongoing development of large models may drive advancements in this sector [2]. Investment Opportunities - Key areas for investment in 2024 include large-scale equipment updates, overseas expansion of machinery, AI applications, and new technology penetration [3].

Investment Rating - The report maintains a "Recommended" rating for the technology sector, particularly focusing on Hong Kong technology investment opportunities due to improved liquidity and policy expectations [1]. Core Insights - The report highlights significant advancements in AI technology, particularly with OpenAI's release of the new complex reasoning model series, OpenAI o1, which shows enhanced reasoning capabilities and performance improvements over previous models [1][19]. - The report notes that the Hang Seng Technology Index rose by 6.44% during the week of September 13 to 20, driven by improved liquidity and positive domestic policy expectations, indicating a favorable investment environment for quality technology companies in Hong Kong [1][7]. Summary by Sections Global Market Performance - The technology stocks experienced a broad increase, with the Hang Seng Technology Index up 6.44%, and other indices like the S&P 500 and NASDAQ also showing gains of 1.36% and 1.49% respectively [1][7]. - The report indicates that the U.S. 10-year Treasury yield rose to 3.73%, reflecting a 7 basis points increase, while the USD/CNY exchange rate was reported at 7.06, up 386 basis points from the previous week [8]. Industry News - The report discusses the launch of AMD's Strix Halo processor series, which aims to cater to high-end and workstation markets with various configurations [12]. - It also mentions that Ampere Computing is exploring potential sale options, which could impact the Arm server CPU market [13][14]. - OpenAI's new model, o1, is noted for its ability to perform complex reasoning tasks and generate code, with performance metrics indicating it can rival human experts in specific domains [19]. Individual Company Financial Reports - Kingdee International's half-year report shows continued progress in its cloud strategy, achieving revenue of 2.87 billion RMB, a year-on-year increase of 11.85%, despite a net loss of 218 million RMB [26].

公司深度报告 · 医药行业 长效蛋白药物龙头,看好派格宾持续放量 特宝生物深度报告 ● 重组蛋白长效制剂领军者,股权激励彰显高增长信心。特宝生物是国内童组 蛋白长效制剂药物龙头企业,自 1996年上市以来,公司已上市 5个产品,依 次为特尔立(1997)、特尔津(1999)、特尔康(2005)、派格宾(2016)、 氟金(2023)。依托在乙肝临床治愈领域的良好表现,派格宾快速成长为公司 核心产品,当前正处于高速放量期;同时借助三大核心平台技术,公司创新研 发管线也稳步推进,长效升白药氟金已上市,长效生长激素 NDA已受理、上 市在即,即将贡献业绩新增量。2024年8月,公司发布股权激励计划,考核 目标分别对应 2024-2026 年度净利润同比增长 30%、30.8%和 29.4%,未来 三年业绩高增长目标明确。 ● 乙肝临床治愈前景广阔,看好派格宾未来持续放量。国内慢乙肝患者规模庞 大,临床治愈是理想治疗目标,目前权威防治指南均建议患者接受抗病毒治疗, 现有的抗病毒药物包括聚乙二醇干扰素和核苷(酸)类药物。派格宾是国内唯 一上市的长效干扰素药物,真实世界研究珠峰项目揭示,长效干扰素将慢乙肝 临床治愈率从3 ...

Core Views - The report emphasizes a "stability first" approach in economic policy, focusing on stabilizing growth, employment, markets, and expectations [5][6] - A comprehensive set of monetary policy tools has been introduced, exceeding market expectations, including a 50 basis point reduction in the reserve requirement ratio, releasing approximately 1 trillion yuan in liquidity [5][6] - The report outlines the importance of stabilizing the capital market, with new monetary policy tools aimed at supporting stock market stability and boosting investor confidence [7][8] Economic Policy Insights - The central bank's monetary policy goals prioritize supporting stable economic growth, followed by promoting moderate price recovery and ensuring the health of the banking sector [5][6] - Future policy expectations suggest a shift towards consumption promotion, with potential incremental fiscal policies on the horizon [5][6] Market Recommendations - In the stock market, the report anticipates a recovery trend in A-shares due to the positive impact of newly introduced policies, with a focus on the recovery slope of macroeconomic fundamentals [7][8] - The bond market is expected to benefit from increased liquidity due to the reserve requirement cut, leading to lower bond yields and enhanced market attractiveness, particularly for short-term bonds [7][8]

Core Insights - The overall trading activity of the Sci-Tech Innovation Board decreased, with an average daily trading volume of approximately 28.21 billion yuan, slightly down from 28.22 billion yuan the previous week [6][7] - The overall PE (TTM) of the Sci-Tech Innovation Board is 31.30, which is higher than the ChiNext, Shanghai and Shenzhen main boards, while the PB is 2.35 [6][8] - The industries with the highest revenue growth in H1 2024 include pharmaceuticals, electronics, public utilities, and communications, all exceeding the GDP growth rate for the same period [23][24] Market Overview - The average turnover rate of the Sci-Tech Innovation Board was 3.32%, lower than that of the ChiNext, North Exchange, and Shanghai and Shenzhen main boards [6][8] - The total market capitalization of the Sci-Tech Innovation Board reached 48,375.03 billion yuan as of September 20, 2024, with a total of 575 listed companies [6][7] Industry Performance - The electronic industry has the highest average PE at 57.84, while the environmental protection industry has the lowest at 18.35 [12][13] - In H1 2024, seven industries saw a year-on-year increase in net profit, with the highest growth rates in communications, public utilities, and household appliances, all exceeding 10% [23][24] - The revenue growth rates for H1 2024 across various industries were led by pharmaceuticals (26.60%), electronics (24.50%), and public utilities (23.74%) [23][24] Comparison with ChiNext - The revenue growth rates of corresponding industries in the Sci-Tech Innovation Board and ChiNext showed significant differences, with the electronic and communication industries performing notably better in the Sci-Tech Innovation Board [23][24] - The net profit growth rates for the computer industry in H1 2024 were 7% for the Sci-Tech Innovation Board and -144% for the ChiNext, indicating a stark contrast in performance [23][24] Fund and Index Performance - The overall performance of index funds related to the Sci-Tech Innovation Board was weaker than the Sci-Tech index itself, with some thematic funds outperforming the overall board [6][8] - The Sci-Tech 50 index has shown a significant decline since August 2022, indicating a challenging market environment [18][19]

Investment Rating - The report maintains a "Recommended" rating for the company [2][3]. Core Insights - The company, TeBao Bio, is a leader in long-acting recombinant protein drugs, with its core product, Pegasys, experiencing rapid growth due to its unique position in the hepatitis B treatment market [1][2]. - The company has launched five products since its listing in 1996, with Pegasys being the only long-acting interferon drug available in China, significantly improving the clinical cure rate for chronic hepatitis B patients [1][2]. - The company has set ambitious profit growth targets through an equity incentive plan, aiming for a net profit growth of 30% for 2024, 30.8% for 2025, and 29.4% for 2026 [1][2]. Summary by Sections Company Overview - TeBao Bio focuses on the research, development, production, and sales of recombinant proteins and their long-acting modified drugs, having launched its first product in 1997 and becoming a publicly listed company in 2020 [1][13]. Product Performance - Pegasys has become the company's absolute core product, generating revenue of 1.79 billion yuan in 2023, accounting for 85.24% of total revenue, with a year-on-year growth of 54.18% [26][49]. - The company’s other products, including Terli and Terkin, have maintained stable sales, while new products like FluJin and Yipeisheng are expected to contribute significantly to future revenue [2][9]. Market Potential - The domestic market for chronic hepatitis B treatment is vast, with an estimated 5-6 million patients, and Pegasys has a low penetration rate of 6.4%, indicating significant growth potential as awareness and treatment rates improve [1][2]. Financial Projections - The company forecasts net profits of 778.79 million yuan in 2024, 1.065 billion yuan in 2025, and 1.380 billion yuan in 2026, with profit growth rates of 40.21%, 36.76%, and 29.59% respectively [8][2]. Research and Development - TeBao Bio has invested heavily in R&D, with a total expenditure of 280 million yuan in 2023, representing 13.33% of revenue, and is focused on advancing multiple key projects, including long-acting growth hormones and other innovative therapies [45][48]. Equity Incentive Plan - The company announced an equity incentive plan in August 2024, granting 6 million restricted shares to employees, with performance targets linked to net profit growth over the next three years [29][31].

Monetary Policy Actions - The People's Bank of China (PBOC) will lower the reserve requirement ratio by 0.5 percentage points, providing approximately 1 trillion yuan in long-term liquidity to the financial market[11] - The PBOC plans to reduce the 7-day reverse repurchase rate by 0.2 percentage points, from 1.7% to 1.5%[11] - This marks the largest single reduction in policy rates since 2021, with expectations for further reductions in the loan market rate and deposit rates by 0.2 to 0.25 percentage points[11] Real Estate Policies - Five new real estate financial policies will be implemented, including lowering existing mortgage rates to align with new loan rates, with an average reduction of about 0.5 percentage points[16] - The minimum down payment for second homes will be reduced from 25% to 15% nationwide[16] - The deadline for two key financial policy documents will be extended to December 31, 2026, enhancing support for real estate market stability[21] Capital Market Support - The PBOC will introduce new structural monetary policy tools to support the stability of the stock market and boost investor confidence[27] - A new mechanism will allow securities, funds, and insurance companies to swap assets for liquidity, enhancing their funding capabilities[28] - A special re-loan program will be established to support stock buybacks and increases by listed companies, with an initial quota of 3 billion yuan[32] Regulatory Enhancements - The China Securities Regulatory Commission (CSRC) will implement measures to enhance the stability of the capital market and protect the rights of small investors[35] - The CSRC aims to attract more long-term capital into the market, improving liquidity and valuation levels[35] - Financial regulatory authorities will continue to optimize policies for large banks, small and micro enterprises, and real estate financing coordination[45]

行业点评报告 ·银行业 从息差、风险和资本视角看政策组合拳影响 国新办金融支持经济高质量发展新闻发布会点评 2024 年 09 月 24 日 ● 事件:国新办举行新闻发布会,介绍金融支持经济高质量发展有关情况。 ● 降息和存量按揭利率调整,降低居民信贷成本、促进消费:央行宣布下调 7 天逆回购利率20BP 至 1.5%,引导 LPR下行。假设 1 年期、5 年期 LPR 下行 20BP,我们测算降息预计降低上市银行资产端收益率 12BP。与此同时,居民 存量房贷利率下调 50BP,有助于缓解存量和增量利率差距过大问题,为居民 节约利息支出,利好消费。经测算,存量按揭利率约为4.13%,与新发放按揭 贷款利率仍有较大差距。调整后将惠及 5000 万户家庭, 1.5 亿人口,平均每 年减少家庭利息支出约 1500亿元,叠加存量利率下行后早偿率下降,预计首 年释放约 6043.5亿元资金用于消费,带动社零总额提升约1.93%。 ● | --- | --- | |--------|-------| | | | | 银行 | | | 推荐 | | | 分析师 | | 张一纬 ☎: 010-8092-7617 网:zha ...

行业点评: 房地产行业 供需两端全面发力，政策空间再打开 9 月 24 日央行政策点评 ● ● 事件:2024年9月24日,国新办举行新闻发布会,央行、金管局、证监会等 部门介绍金融支持经济高质量发展有关情况。央行会同金融监管总局出台五项 房地产金融的政策。 集中出台政策全方位支持房地产行业 2024年9月24日,央行会同金融监 管总局出台五项房地产金融的新政策:引导银行降低存量房贷利率、统一房贷 最低首付比例至 15%、延长两项房地产金融政策文件的期限、优化保障性住 房再贷款政策、支持收购房企存量土地。如上 5 条新政分别针对楼市存量市 场、楼市需求侧、楼市供给侧、楼市库存侧以及房企存量土地给予支持。 ● 存量:降低居民房贷压力央行提到引导银行降低存量房贷利率,至新发放房 贷利率附近,预计平均降幅在 0.5个百分点左右。银行下调存量房贷利率,有 利于进一步降低借款人房贷利息支出,央行预计此次降存量房贷利率有望惠及 5000万户家庭,平均每年减少家庭的利息支出总数约为1500亿元左右,或将 提高居民房贷外的可支配收入,有助于扩大居民端的消费和投资,间接维护房 地产市场的平稳健康发展。 ● 增量:持续支持改善性 ...